Patents by Inventor Scott E. Schaus

Scott E. Schaus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220112206
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, John A. KAVOURIS, Emily A. YORK, Niranjana POKHAREL
  • Patent number: 11242353
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 8, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, John A. Kavouris, Emily A. York, Niranjana Pokharel
  • Publication number: 20210230173
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 29, 2021
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, John A. KAVOURIS, Emily A. YORK, Niranjana POKHAREL
  • Patent number: 9567331
    Abstract: Provided herein are novel small molecule pyridomyrimidone viral inhibitor agents of Formula (I), such as 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[1,2-f]pyrimidin-1-one, and methods of using pharmaceutical or therapeutic compositions comprising such viral inhibitor agents of Formula (I) in inhibiting and treating viral infections including orthopox and retroviral infections. Methods of synthesizing such agents are also provided herein.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: February 14, 2017
    Assignee: Trustees of Boston University
    Inventors: Scott E. Schaus, Lauren Brown, John Connor, Ken William Dower
  • Patent number: 9399644
    Abstract: The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 26, 2016
    Assignee: Trustees of Boston University
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • Publication number: 20150344491
    Abstract: The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Application
    Filed: June 12, 2015
    Publication date: December 3, 2015
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, Joshua A. BISHOP
  • Patent number: 9175001
    Abstract: The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: November 3, 2015
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • Publication number: 20140288095
    Abstract: Provided herein are novel small molecule pyridomyrimidone viral inhibitor agents of Formula (I), such as 4-acetyl-2,3,7,8-tetrahydro-3-phenylpyrido[1,2-f]pyrimidin-1-one, and methods of using pharmaceutical or therapeutic compositions comprising such viral inhibitor agents of Formula (I) in inhibiting and treating viral infections including orthopox and retroviral infections. Methods of synthesizing such agents are also provided herein.
    Type: Application
    Filed: November 15, 2012
    Publication date: September 25, 2014
    Inventors: Scott E. Schaus, Lauren Brown, John Connor, Ken William Dower
  • Publication number: 20140249312
    Abstract: The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 4, 2014
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • Publication number: 20100234348
    Abstract: The present invention provides compounds that potentiate the activity of antibiotic agents, particularly quinolones such as norflaxin. The invention further provides compositions, e.g., pharmaceutical compositions, comprising the inventive compounds. The invention also provides compositions comprising an antibiotic (e.g., a quinolone) and a compound that potentiates activity of the antibiotic. The invention further provides methods of treating a subject comprising administering any of the inventive compounds or compositions to the subject. The invention also provides screening methods to identify compounds that potentiate the activity of an antibiotic, e.g., a quinolone.
    Type: Application
    Filed: August 2, 2007
    Publication date: September 16, 2010
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Guillaume Cottarel, Timothy S. Gardner, Xiaoguang Lei, John Porco, Scott E. Schaus, Jamey Wierzbowski, Kollol Pal
  • Patent number: 6369223
    Abstract: The present invention relates to a process for stereoselective cycloaddition reactions which generally comprises a cycloaddition reaction between a pair of substrates, each either chiral or prochiral, that contain reactive &pgr;-systems, in the presence of a non-racemic chiral catalyst, to produce a stereoisomerically enriched product. The present invention also relates to novel asymmetric catalyst complexes comprising a metal and an asymmetric tridentate ligand.
    Type: Grant
    Filed: January 4, 2001
    Date of Patent: April 9, 2002
    Assignee: President and Fellows of Harvard College
    Inventors: Eric N. Jacobsen, Scott E. Schaus, Alexander G. Dossetter, Timothy F. Jamison
  • Publication number: 20020004602
    Abstract: The present invention relates to a process for stereoselective cycloaddition reactions which generally comprises a cycloaddition reaction between a pair of substrates, each either chiral or prochiral, that contain reactive &pgr;-systems, in the presence of a non-racemic chiral catalyst, to produce a stereoisomerically enriched product. The present invention also relates to novel asymmetric catalyst complexes comprising a metal and an asymmetric tridentate ligand.
    Type: Application
    Filed: January 4, 2001
    Publication date: January 10, 2002
    Inventors: Eric N. Jacobsen, Scott E. Schaus, Alexander G. Dossetter, Timothy F. Jamison
  • Patent number: 6211370
    Abstract: The present invention relates to a process for stereoselective cycloaddition reactions which generally comprises a cycloaddition reaction between a pair of substrates, each either chiral or prochiral, that contain reactive &pgr;-systems, in the presence of a non-racemic chiral catalyst, to produce a stereoisomerically enriched product. The present invention also relates to novel asymmetric catalyst complexes comprising a metal and an asymmetric tridentate ligand.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: April 3, 2001
    Assignee: Harvard University
    Inventors: Eric N. Jacobsen, Scott E. Schaus, Alexander G. Dossetter, Timothy F. Jamison
  • Patent number: 6130340
    Abstract: The present invention relates to a process for stereoselective cycloaddition reactions which generally comprises a cycloaddition reaction between a pair of chiral or prochiral substrates that contain reactive .pi.-systems, in the present of a non-racemic chiral catalyst, to produce a stereoisomerically enriched product.
    Type: Grant
    Filed: January 13, 1998
    Date of Patent: October 10, 2000
    Assignee: President and Fellows of Harvard College
    Inventors: Eric N. Jacobsen, Scott E. Schaus